Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

July 17, 2013

Study Completion Date

September 26, 2017

Conditions
Melanoma
Interventions
DRUG

ipilimumab

Excisional Biopsy - baseline Induction ipilimumab 10 mg/kg IV day 0, 21 - baseline and week 3 Complete lymph node dissection - week ≥ 6 Maintenance Ipilimumab 10 mg/kg IV - Days 63 (+28 days) and, 84 (+28 days) - (3 weeks apart, starting 2-4 weeks following definitive lymphadenectomy)

Trial Locations (1)

15232

University of Pittsburgh Medical Center/University of Pittsburgh Cancer Institute, Pittsburgh

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Diwakar Davar

OTHER